Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | CCR6 | P51684 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycolic Acid SCHEMBL29471409 | 0.82 | GSK3A (0.58) | GSK3AGSK3BCCR6CA12CA9 | |
| Succinic Acid SCHEMBL4127642 | 0.82 | GSK3A (0.58) | GSK3AGSK3BCCR6TSHR | |
| Bicarbonate SCHEMBL5071661 | 0.81 | GSK3A (0.73) | GSK3AGSK3BCCR6CA9KDM4E | |
| Iodoacetic Acid SCHEMBL27515253 | 0.80 | GSK3A (0.55) | GSK3AGSK3BCCR6CA12CA9 | |
| Chloroacetic Acid SCHEMBL28991877 | 0.80 | GSK3B (0.55) | GSK3AGSK3BCCR6CA12CA9 | |
| Glycine SCHEMBL557375 | 0.80 | GSK3A (0.55) | GSK3AGSK3BCCR6CA12CA9 | |
| Propionic Acid SCHEMBL264767 | 0.80 | GSK3A (0.55) | GSK3AGSK3BCCR6CA12CA9 | |
| Propionic Acid SCHEMBL28981241 | 0.78 | GSK3A (0.52) | GSK3AGSK3BCCR6KDM4EHTT | |
| Glutarate SCHEMBL28390952 | 0.78 | GSK3A (0.52) | GSK3AGSK3BCCR6TSHR | |
| Nitrilotriacetic Acid SCHEMBL6684737 | 0.76 | GSK3A (0.50) | GSK3AGSK3BCCR6KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003078-B2 | Targeted MR imaging agents | BARNES-JEWISH HOSPITAL (US) | 2011-08-23 | — | — | US | disclosed |
| US-20080247943-A1 | Blood Clot-Targeted Nanoparticles | KEREOS, INC. | 2008-10-09 | — | — | US | disclosed |
| EP-1539252-A4 | BLOOD CLOT-TARGETED NANOPARTICLES | BARNES JEWISH HOSPITAL (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007115115-A2 | TARGETED MR IMAGING AGENTS | KEREOS, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20070237721-A1 | TARGETED MR IMAGING AGENTS | KEREOS, INC. | 2007-10-11 | — | — | US | disclosed |
| EP-1572639-A4 | INTEGRIN TARGETED IMAGING AGENTS | BARNES JEWISH HOSPITAL (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1572639-A1 | INTEGRIN TARGETED IMAGING AGENTS | Barnes Jewish Hospital (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1539252-A2 | BLOOD CLOT-TARGETED NANOPARTICLES | Barnes-Jewish Hospital (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040058951-A1 | Integrin targeted imaging agents | LANTHEUS MEDICAL IMAGING, INC. | 2004-03-25 | — | — | US | disclosed |
| WO-2004017907-A2 | BLOOD CLOT-TARGETED NANOPARTICLES | BARNES-JEWISH HOSPITAL (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-2003062198-A1 | INTEGRIN TARGETED IMAGING AGENTS | BARNES JEWISH HOSPITAL (US) | 2003-07-31 | — | — | WO | disclosed |
| US-5045233-A | Storage stability | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JP) | 1991-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247943-A1 | Blood Clot-Targeted Nanoparticles | FGB, PLAT, PLG | GSK3A 4643/4885GSK3B 4578/4885CCR6 3054/4885 |
| US-20040058951-A1 | Integrin targeted imaging agents | ITGB3, ITGAV, ITGB1 | GSK3A 2411/4885GSK3B 2501/4885CCR6 1340/4885 |
| US-20070237721-A1 | TARGETED MR IMAGING AGENTS | TSPO, ARNT, RXFP4 | GSK3A 4222/4885GSK3B 4220/4885CCR6 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.